A Registry Study on HIV-related Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRotkreuzklinikum München gGmbH
About this trial
Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
HIV-infection at time of lymphoma diagnosis
Lymphoma diagnosis since 01.01.2010
Adult patients ≥ 18 years
Disqualifiers
HIV-diagnosis > 3 months after the diagnosis of malignant lymphoma
Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)
Trial population
Unselected cohort of adults with HIV-lymphoma
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
2-year overall survival (OS)
OS measured from the date of diagnosis to last follow-up or to death from any cause.
Time frame
2 years2
2-year progression-free survival (PFS)
PFS calculated from the date of diagnosis to the time of progression, relapse, or death.
Time frame
2 yearsSecondary outcomes
1
Incidence of relapse (IR)
Based on establised response criteria, e.g. Chesson et al. JCO 2014
Time frame
5 years2
Non-relapse mortality (NRM)
Deaths unrelated to lymphoma
Time frame
5 years3
5-year overall survival (OS)
OS measured from the date of diagnosis to last follow-up or to death from any cause.
Time frame
5 years4
5-year progression-free survival (PFS)
PFS calculated from the date of diagnosis to the time of progression, relapse, or death.
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov